Libset contains lapatinib, a targeted oral medication used in the treatment of certain types of breast cancer. It is especially useful in cancers that test positive for HER2, a protein that promotes the growth of cancer cells. Lapatinib is often used when other treatments have not been effective or in combination with other cancer medicines for a more complete approach.

Mechanism of Action
Lapatinib works by blocking the action of two proteins found on the surface of cancer cells—HER2 and EGFR. These proteins are involved in sending signals that cause the cells to grow and divide. By inhibiting both of these receptors, lapatinib helps to slow down or stop the growth of cancer cells. It binds to the inside of the cell and blocks the signals from being transmitted, offering a more comprehensive blockade compared to drugs that only work on the outside of the cell.

Uses
Libset is primarily used in the treatment of advanced or metastatic HER2-positive breast cancer. It is commonly prescribed in combination with other therapies like capecitabine or hormone therapy, especially when the cancer has stopped responding to first-line treatments like trastuzumab. Its role in targeting HER2 makes it an important option for patients with aggressive forms of breast cancer.

Adverse Effects
The most common side effects of lapatinib include diarrhoea, rash, nausea, fatigue, and hand-foot syndrome. Some patients may also experience changes in liver function or heart rhythm, so regular monitoring through blood tests and ECGs may be recommended. Though side effects can occur, many are manageable with supportive care, allowing patients to continue treatment effectively.